08:31 Fri 28 Jun 2019
ValiRx PLC - Issue of Equity
("
Issue of Equity
The Investor Shares will rank pari passu in all respects with the existing ordinary shares of the Company. Application has been made to the
Following Admission, the Company's enlarged issued share capital will comprise 1,024,057,953 ordinary shares of 0.1p each with voting rights. The Company does not hold any shares in treasury. This figure of 1,024,057,953 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the
As previously announced, the Company's working capital position is dependent on new funds being made available to it and it continues to manage its working capital position carefully.
This announcement contains inside information for the purpose of Article 7 of EU Regulation 596/2014
*** ENDS ***
For more information, please contact:
|
Tel: +44 (0) 20 3008 4416 |
Dr |
Tel: +44 (0) 20 3008 4416 |
|
Tel: +44 (0) 7879 458 364 |
|
|
|
Tel: +44 (0) 20 7213 0880 |
|
|
|
Tel: +44 (0) 20 7399 9400 |
Notes for Editors
About
The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.
Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in
The Company listed on the AIM Market of the
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE